Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Lithium and Renal Impairment: A Review on a Still Hot Topic

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Daily estimates of clinical severity of symptoms in bipolar disorder from smartphone-based self-assessments

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Lithium is established as an effective treatment of mania, of depression in bipolar and unipolar disorder, and in maintenance treatment of these disorders. However, due to the necessity of monitoring and concerns about irreversible adverse effects, in particular renal impairment, after long-term use, lithium might be underutilized.

METHODS: This study reviewed 6 large observational studies addressing the risk of impaired renal function associated with lithium treatment and methodological issues impacting interpretation of results.

RESULTS: An increased risk of renal impairment associated with lithium treatment is suggested. This increased risk may, at least partly, be a result of surveillance bias. Additionally, the earliest studies pointed toward an increased risk of end-stage renal disease associated with lithium treatment, whereas the later and methodologically most sound studies do not.

DISCUSSION: The improved renal outcome found in the more recent lithium studies may be a result of improved monitoring and focus on recommended serum levels (preferentially 0.6-0.8 mmol/L) as compared to poorer renal outcome in studies with patients treated in the 1960s to 1980s.

Original languageEnglish
JournalPharmacopsychiatry
ISSN0176-3679
DOIs
Publication statusPublished - Sep 2018

    Research areas

  • Journal Article

ID: 53465122